Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574631 | 0.86 | SMN1; SMN2 (0.36) | AURKAGRM4SMN1; SMN2 | |
| SCHEMBL12574982 | 0.85 | AURKA (0.32) | AURKA | |
| SCHEMBL12637322 | 0.85 | HDAC1 (0.35) | MAPTMEN1KMT2APOLBHDAC8 | |
| SCHEMBL12638382 | 0.85 | GFER (0.37) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12637405 | 0.82 | RXRA (0.40) | MAPTNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12638921 | 0.82 | L3MBTL1 (0.36) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL12638350 | 0.80 | RAB9A (0.32) | MAPTNPC1RAB9ARXFP1HDAC8 | |
| SCHEMBL12638869 | 0.79 | MAPK14 (0.42) | MAPTNPC1RAB9APOLBKDM4E | |
| SCHEMBL12637809 | 0.78 | MAPT (0.42) | MAPTMEN1KMT2A | |
| SCHEMBL2024224 | 0.78 | AURKA (0.34) | AURKAGRM4HDAC8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | MKI67, TP53, THPO | AURKA 701/4885GRM4 3666/4885MAPT 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.